Key TakeawaysMcKesson said that limited access to weight-loss treatments because of short supplies is negatively impacting its services sales.Fiscal 2025 first-quarter revenue was well short of analysts' estimates.McKesson warned of a slowdown in the growth rate for the unit that services patients on weight-loss medications. McKesson (MCK) shares tumbled Thursday, a day after the healthcare services provider warned that limited supply of GLP-1 weight-loss drugs is hurting sales. McKesson reported first-quar ...

McKesson Corporation (MCK) reported first-quarter fiscal 2025 adjusted earnings per share (EPS) of $7.88, which beat the Zacks Consensus Estimate of $7.16 by 10.1%. The bottom line also improved 8% on a year-over-year basis.Strong earnings were primarily driven by pre-tax gains of $110 million associated with McKesson Ventures' equity investments, which incurred a loss of $7 million in the year-ago quarter. A lower share count also boosted EPS, more than offsetting higher tax outgo.GAAP EPS was $7.00, down ...

McKesson Corporation (NYSE:MCK) Q1 2025 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Rachel Rodriguez - VP of Investor Relations Brian Tyler - Chief Executive Officer Britt Vitalone - Executive Vice President and Chief Financial Officer Conference Call Participants Eric Percher - Nephron Research Stephen Baxter - Wells Fargo Lisa Gill - JPMorgan Michael Cherny - Leerink Partners Allen Lutz - Bank of America Merrill Lynch Stephanie Davis - Barclays Elizabeth Anderson - Evercore ISI ...

For the quarter ended June 2024, McKesson (MCK) reported revenue of $79.28 billion, up 6.4% over the same period last year. EPS came in at $7.88, compared to $7.27 in the year-ago quarter.The reported revenue represents a surprise of -4.72% over the Zacks Consensus Estimate of $83.21 billion. With the consensus EPS estimate being $7.16, the EPS surprise was +10.06%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their nex ...

McKesson (MCK) came out with quarterly earnings of $7.88 per share, beating the Zacks Consensus Estimate of $7.16 per share. This compares to earnings of $7.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.06%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $6.34 per share when it actually produced earnings of $6.18, delivering a surprise of -2.52%.Over the last four quarters ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-13252 McKESSON CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3207296 (State or other juris ...

Exhibit 99.1 McKESSON CORPORATION REPORTS FISCAL 2025 FIRST QUARTER RESULTS First Quarter Highlights: • Consolidated revenues of $79.3 billion increased 6%. • Earnings per diluted share of $7.00 decreased $0.02. • Adjusted Earnings per Diluted Share of $7.88 increased 8%. • McKesson's Board of Directors approved a 15% increase to the quarterly dividend, to $0.71 per share. This marks the eighth consecutive year of dividend increases. • McKesson's Board of Directors approved a $4.0 billion increase to the sh ...

So far in 2024, healthcare stocks have run into periodic earnings challenges compared to historical first quarters. For example, quarterly earnings for healthcare stocks across the board were down 25% compared to first-quarter 2023 earnings. Even with this setback, the healthcare sector maintained positive returns year-to-date and is still the second largest component of the S&P 500’s earnings in 2024, with only the technology sector ahead of it.Moreover, according to U.S. Bank, the healthcare sector modest ...

In its upcoming report, McKesson (MCK) is predicted by Wall Street analysts to post quarterly earnings of $7.16 per share, reflecting a decline of 1.5% compared to the same period last year. Revenues are forecasted to be $83.21 billion, representing a year-over-year increase of 11.7%.Over the last 30 days, there has been an upward revision of 0.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial for ...

McKesson (MCK) closed the most recent trading day at $629.09, moving +1.96% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.37%. Elsewhere, the Dow lost 1.21%, while the tech-heavy Nasdaq lost 2.3%.Prior to today's trading, shares of the prescription drug distributor had gained 5.77% over the past month. This has outpaced the Medical sector's gain of 0.74% and the S&P 500's gain of 1.11% in that time.Investors will be eagerly watching for the performance ...